Vestre Viken HF — Clinical Trial Site

46 Registered trials

31 Currently recruiting

Organisation

Vestre Viken HF

Location

Drammen, Norway

Identifier

ORG-100039605

Address

Valbrottveien 17, 3024, Norway

Departments

anaesthesiology
Avdeling for Atferdsmedisin
Department of Internal Medicine
Department of Medicine
Department of Nephrology
Department of Neurology
Department of Neurology,
Department of Obstetrics and Gynecology
Department of oncology
Department of Oncology (Jacob Borchs gate 10)
Department of Oncology, Surgical Department
Department of Surgery
Department of Surgery, Section of Oncology
Department Oncology
Dept of Oncology
Dept. Of Hematology, Drammen Hospital
Dept. of surgery, section of Oncology
Drammen Hospital, Vestre Viken, Revmatologi
Drammen sykehus
Gastroenterology
General internal medicine and infectious diseases
Kreftpoliklinikken
Medical Department
Neurology
Oncology
Oncology, Baerum
Oncology, Drammen
Oncology, Ringerike
Onkologisk avdeling
Onkologisk Poliklinikk
Palliative Care Unit
Seksjonen for kreftbehandling
Surgery, Oncology
Vestre Viken Trust-Drammen Hospital

Clinical trials at this site (46)

Search interface

IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending

2025-521908-22-00 EGFR-mutated Non-small Cell Lung Cancer 10
TARGET-EBV in MS: Targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate in multiple sclerosis Pending

2025-522140-40-00 multiple sclerosis 4
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c… Recruiting

2023-504308-27-00 non-squamous non-small cell lung cancer 5 2024-06-06
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 … Recruiting

2024-517606-29-00 Central retinal artery occlusion 5 2020-10-30
A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in par… Recruiting

2024-513927-18-00 Amyotrophic Lateral Sclerosis 4 2026-02-16
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-07-16
Aminoglycosides in early sepsis Recruiting

2024-519797-39-00 Sepsis 6 2025-07-01
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Chron's Disease 11 2025-06-02
Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting

2023-509907-34-01 acute ischemic stroke 5 2025-03-10
Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting

2023-509994-22-00 cutaneous malignant melanoma 5 2024-11-15
MOVE-JIA trial Recruiting

2024-513017-12-00 Juvenile Idiopathic Arthritis 6 2024-10-24
The Effect of Topical Tranexamic Acid on Postoperative Complications in Soft Tissue Plastic Surgery. A Multicenter Randomized Controlled Tri… Recruiting

2023-510381-28-01 Patients undergoing plastic surgical procedures with wo 6 2024-09-18
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
Antibiotic THErapy iN vIral Airway iNfections (ATHENIAN): An open labelled randomized controlled pragmatic trial to evaluate the efficacy an… Recruiting

2023-509286-20-00 Viral respiratory tract infection 6 2024-05-15
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04